Nasdaq has suspended trading of OpGen shares after the company failed to provide an adequate plan to regain compliance with the stock exchange's listing requirements. OpGen has been grappling with multiple challenges, including outstanding debt and the recent bankruptcies of its European subsidiaries, Curetis and Ares Genetics.
Earlier this year, OpGen attempted to regain compliance by implementing a one-for-10 reverse stock split to meet Nasdaq’s USD 1 minimum bid price requirement. However, the company faced further setbacks when it failed to file a first-quarter report with the US Securities and Exchange Commission (SEC) and fell short of the Nasdaq’s minimum stockholders’ equity requirement. Despite submitting the overdue report and proposing a plan to regain compliance, the Nasdaq hearing board rejected the plan, leading to the suspension of trading.
In its financial situation, OpGen recently struck a deal to sell up to USD 3 million in common stock to AEI Capital, aiming to boost its shareholder equity and meet Nasdaq's requirements. However, with the suspension of its shares, the status of this deal remains uncertain, and company officials have not provided further comments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.